151 related articles for article (PubMed ID: 37532182)
21. Adult IDH wild-type lower-grade gliomas should be further stratified.
Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
[TBL] [Abstract][Full Text] [Related]
22. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
23. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
24. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.
Guerreiro Stucklin AS; Ryall S; Fukuoka K; Zapotocky M; Lassaletta A; Li C; Bridge T; Kim B; Arnoldo A; Kowalski PE; Zhong Y; Johnson M; Li C; Ramani AK; Siddaway R; Nobre LF; de Antonellis P; Dunham C; Cheng S; Boué DR; Finlay JL; Coven SL; de Prada I; Perez-Somarriba M; Faria CC; Grotzer MA; Rushing E; Sumerauer D; Zamecnik J; Krskova L; Garcia Ariza M; Cruz O; Morales La Madrid A; Solano P; Terashima K; Nakano Y; Ichimura K; Nagane M; Sakamoto H; Gil-da-Costa MJ; Silva R; Johnston DL; Michaud J; Wilson B; van Landeghem FKH; Oviedo A; McNeely PD; Crooks B; Fried I; Zhukova N; Hansford JR; Nageswararao A; Garzia L; Shago M; Brudno M; Irwin MS; Bartels U; Ramaswamy V; Bouffet E; Taylor MD; Tabori U; Hawkins C
Nat Commun; 2019 Sep; 10(1):4343. PubMed ID: 31554817
[TBL] [Abstract][Full Text] [Related]
25. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
Qaddoumi I; Orisme W; Wen J; Santiago T; Gupta K; Dalton JD; Tang B; Haupfear K; Punchihewa C; Easton J; Mulder H; Boggs K; Shao Y; Rusch M; Becksfort J; Gupta P; Wang S; Lee RP; Brat D; Peter Collins V; Dahiya S; George D; Konomos W; Kurian KM; McFadden K; Serafini LN; Nickols H; Perry A; Shurtleff S; Gajjar A; Boop FA; Klimo PD; Mardis ER; Wilson RK; Baker SJ; Zhang J; Wu G; Downing JR; Tatevossian RG; Ellison DW
Acta Neuropathol; 2016 Jun; 131(6):833-45. PubMed ID: 26810070
[TBL] [Abstract][Full Text] [Related]
26. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
27. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
28. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract][Full Text] [Related]
29. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
30. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
Paugh BS; Qu C; Jones C; Liu Z; Adamowicz-Brice M; Zhang J; Bax DA; Coyle B; Barrow J; Hargrave D; Lowe J; Gajjar A; Zhao W; Broniscer A; Ellison DW; Grundy RG; Baker SJ
J Clin Oncol; 2010 Jun; 28(18):3061-8. PubMed ID: 20479398
[TBL] [Abstract][Full Text] [Related]
31. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
32. [Pediatric Glioma].
Terashima K; Ogiwara H
No Shinkei Geka; 2021 May; 49(3):640-646. PubMed ID: 34092570
[TBL] [Abstract][Full Text] [Related]
33. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
Patel RR; Ramkissoon SH; Ross J; Weintraub L
Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
[TBL] [Abstract][Full Text] [Related]
34. Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia.
Mobark NA; Alharbi M; Alhabeeb L; AlMubarak L; Alaljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Ahmad M; Al-Banyan A; Alotabi FE; Barakeh D; AlZahrani M; Al-Khalidi H; Ajlan A; Ramkissoon LA; Ramkissoon SH; Abedalthagafi M
PLoS One; 2020; 15(1):e0228356. PubMed ID: 31995621
[TBL] [Abstract][Full Text] [Related]
35. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Bao ZS; Chen HM; Yang MY; Zhang CB; Yu K; Ye WL; Hu BQ; Yan W; Zhang W; Akers J; Ramakrishnan V; Li J; Carter B; Liu YW; Hu HM; Wang Z; Li MY; Yao K; Qiu XG; Kang CS; You YP; Fan XL; Song WS; Li RQ; Su XD; Chen CC; Jiang T
Genome Res; 2014 Nov; 24(11):1765-73. PubMed ID: 25135958
[TBL] [Abstract][Full Text] [Related]
36. Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death.
Ahrendsen JT; Sinai C; Meredith DM; Malinowski SW; Cooney TM; Bandopadhayay P; Ligon KL; Alexandrescu S
J Neuropathol Exp Neurol; 2021 Nov; 80(11):1052–1059. PubMed ID: 34580728
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
Wang LM; Wang W; Liu L; Gao M; Yao YY; Zhang M; Xiong YL; Shao Y; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):734-739. PubMed ID: 34405606
[No Abstract] [Full Text] [Related]
38. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
Ramkissoon LA; Horowitz PM; Craig JM; Ramkissoon SH; Rich BE; Schumacher SE; McKenna A; Lawrence MS; Bergthold G; Brastianos PK; Tabak B; Ducar MD; Van Hummelen P; MacConaill LE; Pouissant-Young T; Cho YJ; Taha H; Mahmoud M; Bowers DC; Margraf L; Tabori U; Hawkins C; Packer RJ; Hill DA; Pomeroy SL; Eberhart CG; Dunn IF; Goumnerova L; Getz G; Chan JA; Santagata S; Hahn WC; Stiles CD; Ligon AH; Kieran MW; Beroukhim R; Ligon KL
Proc Natl Acad Sci U S A; 2013 May; 110(20):8188-93. PubMed ID: 23633565
[TBL] [Abstract][Full Text] [Related]
39. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Sievers P; Stichel D; Sill M; Schrimpf D; Sturm D; Selt F; Ecker J; Kazdal D; Miele E; Kranendonk MEG; Tops BBJ; Kohlhof-Meinecke P; Beschorner R; Kramm CM; Hasselblatt M; Reifenberger G; Capper D; Wesseling P; Stenzinger A; Milde T; Korshunov A; Witt O; Pfister SM; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Dec; 142(6):1065-1069. PubMed ID: 34536122
[No Abstract] [Full Text] [Related]
40. Targetable molecular alterations in congenital glioblastoma.
Gilani A; Donson A; Davies KD; Whiteway SL; Lake J; DeSisto J; Hoffman L; Foreman NK; Kleinschmidt-DeMasters BK; Green AL
J Neurooncol; 2020 Jan; 146(2):247-252. PubMed ID: 31875306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
